Skip to content
Peptigraph home

Retatrutide Phase 2 trial (NCT04881760)

A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
338
actual
Start
20 May 2021 (actual)
Primary completion
16 May 2022 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT04881760 study arms
ArmTypeInterventionsDescription
PlaceboPlacebo comparatorDrug: PlaceboParticipants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).
1 milligram (mg) LY3437943ExperimentalDrug: LY3437943Participants received 1 mg LY3437943 administered as SC injection QW.
4 mg LY3437943 (2 mg)ExperimentalDrug: LY3437943Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
4 mg LY3437943ExperimentalDrug: LY3437943Participants received 4 mg LY3437943 administered as SC injection QW.
8 mg LY3437943 (2 mg)ExperimentalDrug: LY3437943Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
8 mg LY3437943 (4 mg)ExperimentalDrug: LY3437943Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.
12 mg LY3437943 (2 mg)ExperimentalDrug: LY3437943Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.
Endpoints

Primary endpoint

NCT04881760 primary outcomes
MeasureTime frame
Mean Percent Change From Baseline in Body WeightBaseline, Week 24
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT04881760 secondary outcomes
MeasureTime frame
Mean Percent Change From Baseline in Body WeightBaseline, Week 48
Percentage of Participants Who Achieve ≥ 5% Body Weight ReductionWeek 24
Percentage of Participants Who Achieve ≥ 5% Body Weight ReductionWeek 48
Percentage of Participants Who Achieve ≥ 10% Body Weight ReductionWeek 24
Percentage of Participants Who Achieve ≥ 10% Body Weight ReductionWeek 48
Percentage of Participants Who Achieve ≥ 15% Body Weight ReductionWeek 24
Percentage of Participants Who Achieve ≥ 15% Body Weight ReductionWeek 48
Mean Change From Baseline in Body WeightBaseline, Week 24
Mean Change From Baseline in Body WeightBaseline, Week 48
Mean Change From Baseline in BMIBaseline, Week 24
Mean Change From Baseline in BMIBaseline, Week 48
Mean Change From Baseline in Waist CircumferenceBaseline, Week 24
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT04881760.

The obesity phase 2 trial of retatrutide in the New England Journal of Medicine

Participants were randomised 2:1:1:1:1:2:2 to weekly retatrutide from 1 mg to 12 mg, with 4 mg and 8 mg arms split by a 2 mg or 4 mg starting dose, or placebo for 48 weeks.[2]

At 48 weeks weight changed by -8.7% on 1 mg, -17.1% on combined 4 mg, -22.8% on combined 8 mg and -24.2% on 12 mg, against -2.1% on placebo.[2]

Gastrointestinal events were dose-related and partially mitigated by a lower starting dose of 2 mg rather than 4 mg.[2]

Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.[2]

The liver fat substudy

Mean relative change in liver fat at 24 weeks was -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), -82.4% (12 mg) and +0.3% on placebo.[3]

Normal liver fat (under 5%) was reached by 27%, 52%, 79% and 86% of participants across the four retatrutide doses, and 0% on placebo.[3]

Sources

  1. 1A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related ComorbiditiesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
  3. 3Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.Nature medicine · 2024PMID 38858523Accessed 2 Oct 2026

Found an error? Report a correction.